Investor Relations :: ContraFect Corporation (CFRX)

Latest News

ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study

Oct 16, 2023

Latest Financial Results

Company Overview

ContraFect is a clinical-stage biotechnology company focused on discovering and developing biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of direct lytic agents (DLAs), which include lysins and amurin peptides. We believe DLAs provide the opportunity to make meaningful improvements to clinical outcomes and to change the treatment paradigm for patients infected with antibiotic-resistant bacteria. Our initial product candidates are new agents to treat lethal, resistant infections such as methicillin-resistant Staph aureus (MRSA) and Gram-negative pathogens like multi-drug resistant (MDR) Pseudomonas aeruginosa.

Officers & Directors

Jane E. Ambler, Ph.D.

Vice President of Clinical Microbiology

Dr. Ambler has served as our Vice President of Clinical Microbiology since February 2020. Dr. Ambler has over 25 years of experience working in antibacterial drug development in the pharmaceutical industry and a hospital antibi...

View Full Profile »

Nancy Capra

Vice President of Program Management and Development Operations

Ms. Capra has served as our Vice President of Program Management and Development Operations since February 2021. Prior to that, she had served as Executive Director of Program Management since November 2015. Ms. Capra is a Cert...

View Full Profile »

W. Garrett Nichols, M.D., M.S.

Interim Chief Medical Officer

Dr. Nichols joined ContraFect as our Interim Medical Officer in August 2022. With more than 20 years in the life sciences industry, Dr. Nichols brings vast experience managing the global development efforts of multiple ca...

View Full Profile »

Roger J. Pomerantz, M.D., F.A.C.P.

President, Chief Executive Officer and Chairman of the Board

Dr. Pomerantz has served as Chairman of our board of directors and our Chief Executive Officer since April 2019. Prior to that, he had served as Vice Chairman of our board of directors since May 2014. From November 2013 to Dece...

View Full Profile »

Matthew Salamone, SPHR, PHR

Vice President of Human Resources

Mr. Salamone joined ContraFect in October 2020 and currently serves as our Vice President of Human Resources. He brings over 15 years of experience being a strategic partner within management and executive teams, assistin...

View Full Profile »

Raymond Schuch, Ph.D.

Vice President of Research

Dr. Schuch joined ContraFect in 2011 as the VP of Research where his work has supported the continued development of exebacase from IND candidacy through to our ongoing Phase 3 clinical trial. Prior to ContraFect, Dr. Schuch he...

View Full Profile »

Gary Woodnutt, Ph.D.

Senior Vice President of Translational Sciences and Preclinical Development

Dr. Woodnutt joined ContraFect in June 2021 as the Senior Vice President of Translational Sciences and Preclinical Development. He brings over 30 years of experience leading the discovery and development of innovative therapies...

View Full Profile »

Annaliesa Anderson, PhD, FAAM

Science & Technology Committee Observer

Dr. Anderson is an Observer on our Science & Technology Committee. She has over 20 years of pharmaceutical research and development experience and is currently the Vice President and Chief Scientific Officer for Bacte...

View Full Profile »

Nasdaq: CFRX